At year-end 2023, the group had a net debt position of c.€18m. The bulk of the capex has been spent (i.e. the industrial investment needed for the production of c.1.5m Zeneo devices). This includes €3.8m in capex in 2014-15, €3.2m in FY18, €4.4m in FY19 and another €6m in FY20 as well as a”recurring” net capex of about €3m yearly. Looking onwards, we have considered a recurring capex (€2m) to which is added an “expansion” capex of €3m for each additional 2.5m units sold (which is probably not the way capex will be spent since these “thresholds” do not necessarily require such high levels of investment). Another important issue before first sales are booked is the amount needed to finance the clinical studies. According to management, the full development of each NTE costs c. €2-3m (including clinical studies) and is spent in the two years preceding market approval. This comes on top of the “normal” cash-burn of the company before its products are on shelves. However, Crossject will also benefit from upfront fees once partnership agreements are signed, on top of the benefit for tax credits and the remaining part of the “PIAVE” financing. At the end of the day, our view is that the group is self-financed provided it is able to sign partnerships in the short term. Otherwise, Crossject may have to resort to the financial markets or find another financial solution to raise cash (for instance, by “selling” future royalties to a financial partner). The group, which has already resorted to capital increases to finance its short-term needs (first through an equity line in place since FY16 and a €5m capital increase in March 2017), has issued a €5.3m convertible bond in March 2018 and another €2.5m in July. A €3.9m capital increase was announced on 28 November 2018, at a price of €1.16, with the new 3.4m shares listed before the year-end (28 December 2018). The conversion of convertible bonds in FY19 has reduced bond debt by c. €5m. At the end of FY19, the group issued a new convertible bond worth €5.7m.
More recently, the group issued two bonds (each worth €5.24m, one of which is a convertible) in December 2020. The group also issued €7.5m worth of convertible bonds in December 2021, with a conversion price of the minimum between €3.30 and 92% of the market price while existing shareholders were granted a free subscription price (with 20 rights needed to buy one share). In February 2024, the group announced the issue of 70 amortizable bonds convertible into new stock with a nominal value of €100,000, in the amount of €7m, waiving preferential subscription rights.
In April 2024, the latest issue concerned a capital increase of €8m, mainly to finance the launch of Zepizure in the US (€6m) and the development costs on other NTEs (Hydrocortisone and Epinephrin).
